Quantcast

Industry news that matters to you.  Learn more

Archives for November 2014

IBM Watson Group Invests in Pathway Genomics to Help Personalize Consumer Health

Cognitive apps are in market today and continue to change the way professionals and consumers make decisions. To help accelerate this transformation, the IBM Watson Group (NYSE: IBM) announced an investment in Pathway Genomics Corporation, a clinical laboratory that offers genetic testing services globally, to help deliver the first-ever cognitive consumer-facing app based on genetics from a user’s personal makeup.

Caris Life Sciences Study Shows Molecular Profiling May Expand Use of PD-1 and PD-L1 Inhibitors to Wide Variety of Cancers

Caris Life Sciences, a biosciences company focused on fulfilling the promise of precision medicine, recently announced the publication of a study in which Caris Molecular Intelligence™, the company’s panomic, comprehensive tumor profiling service, demonstrated the utility of exploring the expression of two potentially targetable immune checkpoint proteins – the programmed cell death protein 1 (PD-1) and its ligand, PD-L1 – in a substantial proportion of solid tumors. The study results, published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, may expand the use of PD-1 and PD-L1 inhibitors, a new class of anticancer drugs, to a wide variety of solid tumors, including some aggressive subtypes that lack targeted treatment regimens.

ACLA Retains Attorneys Paul D. Clement and Laurence H. Tribe To Represent ACLA in Opposing the FDA’s Proposal To Treat Laboratory Developed Tests (LDTs) as Medical Devices

The American Clinical Laboratory Association (ACLA) announced today that it has retained former Solicitor General Paul D. Clement, a partner with Bancroft PLLC, and Laurence H. Tribe, the Carl. M. Loeb University Professor and Professor of Constitutional Law at Harvard University, and a distinguished scholar working with Massey & Gail LLP, for representation on matters relating to the Food and Drug Administration’s (FDA) recently issued draft guidance to regulate laboratory developed tests (LDTs) as medical devices.

bioTheranostics’ Breast Cancer Index Genomic Test Selected as Finalist in 27th Annual CONNECT Most Innovative New Product Awards

bioTheranostics, Inc., a leading genomic solutions provider for cancer, recently announced that its Breast Cancer Index molecular test has been selected as a finalist in the Life Sciences—Diagnostics & Research Tools category for the 2014 Most Innovative New Product Awards, sponsored by CONNECT. CONNECT, a regional program that catalyzes the creation of innovative technology and life sciences products in San Diego County, continues its 27-year tradition of honoring San Diego’s leaders of innovation and groundbreaking new products with the annual award.

Human Longevity, Inc. Signs Collaborative Agreement with King’s College London to Access TwinsUK Registry

Human Longevity, Inc. (HLI), a biological data-driven human health technology and cell therapy company, recently announced a collaborative agreement with King’s College London to access their TwinsUK Registry.